Author

B. Oldrini

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 3

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Research Focus:cancer & tumor microenvironment· 2 Research Focus:cell type annotation· 2 Research Focus:gene regulatory network inference· 2 Organism:human· 2 Organism:mouse· 2 Assay:bulk RNA-seq· 1 Research Focus:differential expression· 1

Frequent Co-Authors

M. Squatrito· 3 shared C. Marques· 2 shared P. Kroon· 2 shared S. Rodriguez-Perales· 2 shared A. Curiel-Garcia· 1 shared A. Izzo· 1 shared D.-H. Nam· 1 shared E. F. Wagner· 1 shared

Activity by Year

2017-2020 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 30 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersCancer Biology

M. Squatrito

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

NF1 regulates mesenchymal glioblastoma plasticity and aggressiveness through the AP-1 transcription factor FOSL1

C. Marques, T. Unterkircher, P. Kroon, A. Izzo, Y. Dramaretska, E. Kling, B. Oldrini, O. Schnell, S. Nelander, E. F. Wagner, L. Bakiri, G. Gargiulo, M. S. Carro, M. Squatrito

The paper identifies FOSL1 as a key regulator of mesenchymal glioblastoma subtype through NF1 modulation, showing its role in plasticity and aggressiveness.

bioRxiv · Nov 6, 2020Cancer Biology

MGMT genomic rearrangements contribute to chemotherapy resistance in gliomas

B. Oldrini, N. Vaquero-Siguero, Q. Mu, P. Kroon, Y. Zhang, M. Galan-Ganga, Z. Bao, Z. Wang, H. Liu, J. K. Sa, J. Zhao, H. Kim, S. Rodriguez-Perales, D.-H. Nam, R. G. Verhaak, , M. Squatrito

This study shows that MGMT genomic rearrangements cause TMZ resistance in gliomas and can be detected in exosomes as potential recurrence markers.

Nature Communications · Aug 4, 2020Peer-reviewedCancer Biology

Somatic genome editing with the RCAS/TVA-CRISPR/Cas9 system for precision tumor modeling

B. Oldrini, A. Curiel-Garcia, C. Marques, V. Matia, O. Uluckan, R. Torres-Ruiz, S. Rodriguez-Perales, J. Huse, M. Squatrito

This paper develops a mouse model using RCAS/TVA-CRISPR/Cas9 for in vivo somatic genome editing to generate accurate cancer models.

bioRxiv · Aug 14, 2017Cancer Biology